AZTA
$20.19-0.44 (-2.13%)
Azenta, Inc.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Azenta, Inc. provides biological and chemical compound sample exploration and management solutions for the life sciences industry in the United States, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. It operates thro...
Recent News
1 Cash-Producing Stock with Exciting Potential and 2 We Ignore
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
3 Unprofitable Stocks That Concern Us
Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, these businesses risk running out of capital or relying on dilutive fundraising.
Azenta Buys UK Biocentre As Valuation Screens Cheap Despite Weak Momentum
Azenta (NasdaqGS:AZTA) announced the acquisition of UK Biocentre Limited. The deal is intended to expand Azenta’s biorepository capabilities. UK Biocentre Limited adds a UK based hub focused on large scale sample processing and storage. For investors following Azenta’s role in life sciences infrastructure, this move adds another piece to its biorepository platform. Azenta provides sample exploration and management solutions that support drug discovery, clinical research, and precision...
Has Azenta (AZTA) Fallen Too Far After Recent Share Price Weakness?
If you are wondering whether Azenta's share price now reflects good value or lingering risks, this article walks through what the numbers actually say about the stock. The shares last closed at US$21.42, and investors have seen returns of an 11.9% decline over 7 days, a 29.7% decline over 30 days, a 35.8% decline year to date, a 41.8% decline over 1 year and a 45.8% decline over 3 years, with a 75.0% decline over 5 years. These moves have put valuation front and center for many shareholders,...
Azenta Details UK Biocentre Buyout to Expand Europe Biobanking, Near-Term EBITDA Dilution Seen
Azenta (NASDAQ:AZTA) executives outlined the strategic and financial rationale for the company’s planned acquisition of UK Biocentre during a recorded conference call held Tuesday, March 10, 2026. Management said the deal is intended to expand Azenta’s European footprint, scale its biorepository ope